Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for heart failure
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Actionable Metabolic Pathways in HeartFailure and Cancerâ€”Lessons From Cancer Cell Metabolism Recent advances in cancer cell metabolism provide unprecedented opportunities for a new understanding of heart metabolism and may offer new approaches for the treatment of heartfailure. Key questions driving the cancer field to understand how tumor cells reprogram metabolism and to benefit tumorigenesis are also applicable to the heart. Recent experimental and conceptual advances in cancer cell (...) metabolism provide the cardiovascular field with the unique opportunity to target metabolism. This review compares cancer cell metabolism and cardiac metabolism with an emphasis on strategies of cellular adaptation, and how to exploit metabolic changes for therapeutic benefit.
in PAP values in patients after MitraClip with PAP changes in patients without MitraClip.Among 28 patients with New York Heart Association III heartfailure with implanted PAP sensor for haemodynamic telemonitoring from a single centre, four patients (age 66 ± 6 years, left ventricular ejection fraction 21 ± 3%, and cardiac index 1.8 ± 0.3) received a MitraClip procedure and were compared with 24 patients (age 72 ± 8 years, left ventricular ejection fraction 26 ± 9.9%, and cardiac index 2.0 ± 1.0 (...) Daily nonâ€invasive haemodynamic telemonitoring for efficacy evaluation of MitraClipÂ® implantation in patients with advanced systolic heartfailure Patients with advanced systolic chronic heartfailure frequently suffer from progressive functional mitral regurgitation. We report our initial experience in patients with an implanted pulmonary artery pressure (PAP) sensor, who developed severe mitral regurgitation, which was treated with the MitraClip system. We non-invasively compared changes
HeartFailure. Heartfailure affects more than 6 million people in the United States and incurs a heavy toll in morbidity, mortality, and health care costs. It frequently coexists with other important disorders, including hypertension, coronary artery disease, diabetes, and obesity. Decades of clinical trials have shown that several medications and interventions are effective for improving outcomes; however, mortality and hospitalization rates remain high. More recently, additional medications (...) and devices have shown promise in reducing the health burden of heartfailure.
Treatment of Atrial Fibrillation in Patients with Co-existing HeartFailure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines? AF in patients with heartfailure and reduced ejection fraction (HFrEF) is common and is associated with an increased risk of stroke, heartfailure hospitalisation and all-cause mortality. Rhythm control of AF in this population has been traditionally limited to the use of antiarrhythmic drugs. Clinical trials assessing superiority
Atrial Fibrillation Ablation in Patients with HeartFailure: One Size Does Not Fit All Atrial fibrillation (AF) is common in patients with heartfailure and is associated with poorer clinical outcomes compared with patients with heartfailure alone. Recent evidence has challenged previous treatment paradigms in which rate control was considered equivalent to rhythm control in this population. Catheter ablation has emerged as a safe and effective treatment strategy in selected patients (...) and overcomes the issues of limited efficacy and drug toxicities associated with pharmacological rhythm control. Numerous studies have explored the benefits of catheter ablation in patients with heartfailure, but these have included heterogeneous patient cohorts and variable ablation strategies. This state-of-the-art review explores the evidence from these trials and examines the need for tailored, patient-specific strategies for AF ablation in patients with heartfailure.
His Bundle Pacing: A New Frontier in the Treatment of HeartFailure Biventricular pacing has revolutionised the treatment of heartfailure in patients with sinus rhythm and left bundle branch block; however, left ventricular-lead placement is not always technically possible. Furthermore, biventricular pacing does not fully normalise ventricular activation and, therefore, the ventricular resynchronisation is imperfect. Right ventricular pacing for bradycardia may cause or worsen heartfailure (...) in some patients by causing dyssynchronous ventricular activation. His bundle pacing activates the ventricles via the native His-Purkinje system, resulting in true physiological pacing, and, therefore, is a promising alternate site for pacing in bradycardia and traditional CRT indications in cases where it can overcome left bundle branch block. Furthermore, it may open up new indications for pacing therapy in heartfailure, such as targeting patients with PR prolongation, but a narrow QRS duration
2018 Circulation. 2018;137:e578–e622 You are viewing the most recent version of this article. Previous versions: Abstract Background and Purpose: The diverse causes of right-sided heartfailure (RHF) include, among others, primary cardiomyopathies with right ventricular (RV) involvement, RV ischemia and infarction, volume loading caused by cardiac lesions associated with congenital heart disease and valvular pathologies, and pressure loading resulting from pulmonic stenosis or pulmonary (...) options and enhanced outcomes in patients with acute and chronic disorders of the right side of the heart. RV dysfunction (RVD), defined here as evidence of abnormal RV structure or function, is associated with poor clinical outcomes independently of the underlying mechanism of disease: across the spectrum of left ventricular (LV) ejection fraction (EF) in patients with acute and chronic heartfailure (HF), after cardiac surgery, acute myocardial infarction (MI), congenital heart disease (CHD), and PH
Effectiveness of a transition plan at discharge of patients hospitalized with heartfailure: a beforeâ€andâ€after study We evaluated the effectiveness of a multidisciplinary transition plan to reduce early readmission among heartfailure patients.We conducted a before-and-after study in a tertiary internal medicine department, comparing 3 years of retrospective data (pre-intervention) and 13 months of prospective data (intervention period). Intervention was the introduction in 2013 (...) of a transition plan performed by a multidisciplinary team. We included all consecutive patients hospitalized with symptomatic heartfailure and discharged to home. The outcomes were the fraction of days spent in hospital because of readmission, based on the sum of all days spent in hospital, and the rate of readmission. The same measurements were used for those with potentially avoidable readmissions. Four hundred thirty-one patients were included and compared with 1441 patients in the pre-intervention
Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an allâ€comer population of patients with heartfailure: a retrospective analysis Aetiology of heartfailure (HF) often remains obscure. We therefore evaluated the usefulness of a combined diagnostic approach including cardiac magnetic resonance imaging (CMRI) and endomyocardial biopsy (EMB) to assess the cause of unexplained cardiomyopathy underlying HF.We retrospectively investigated 100 consecutive (...) patients (36% women, mean age 53.6 ± 18.8 years) presenting with unexplained cardiomyopathy (HF with reduced ejection fraction or left ventricular hypertrophy; excluding ischaemic and valvular heart disease; left ventricular ejection fraction 31.6 ± 13.9%, Left ventricular end-diastolic pressure 18.2 ± 9.3 mmHg, heart rate 89 ± 26.6 b.p.m.; mean ± SEM) at the University Medical Center Mainz. We performed electrocardiography, echocardiography, CMRI, and cardiac catheterization with EMB analysed
Ivabradine (Lancora) - chronic heartfailure Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012
”. The application was transferred to IQWiG on 27 November 2015. According to the applicant, the method applied – hereinafter referred to as “PA pressure monitoring” – aims to detect early haemodynamic changes in the pulmonary circulation of heartfailure patients to help optimize drug treatment and avoid symptoms, cardiac decompensation and hospitalization. Results from a randomized controlled trial (RCT) were available for the method “measurement and monitoring of pulmonary artery pressure via an implanted (...) Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heartfailure 1 Translation of the executive summary of the assessment of potential Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz (Version 1.0; Status: 8 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text
Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heartfailure ? Addendum to Commission E15-04 1 Translation of the executive summary of the addendum Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz – Addendum zum Auftrag E15-04 (Version 1.0; Status: 20 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers (...) . However, solely the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. E16-02 Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heartfailure – Addendum to Commission E15-04 1 Executive summary of Addendum E16-02 Version 1.0 PA pressure monitoring in heartfailure 20 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher